Category Archives: gene therapy article

Viral vector-based vaccines: Adenovirus (AdV) vector-based vaccines

COVID-19 vaccine development protocol: PSV Based Neutralization Assay Adenovirus (AdV) vector-based vaccines Adenovirus (AdV) is a member of the family Adenoviridae, whose name derives from their initial isolation from human adenoids in 1953 [42]. It is a medium sized (90-100nm) and non-enveloped virus with an icosahedral nucleocapsid containing a 36kb double stranded DNA genome (Fig. […]

Viral vector-based vaccines: AAV vector-based vaccines

COVID-19 vaccine development protocol: PSV Based Neutralization Assay Viral vector-based vaccines Viral vector-based vaccines are vaccines that can deliver specific antigen gene to target cells based on the infection ability of viruses, produce antigens via the nutrition substances in host cells, and then provoke immune responses with the newly synthesized antigens. Compared with the traditional […]

Viral vector-based vaccine; DNA-based vaccine; RNA based vaccine- Landscape and Classification of vaccines

COVID-19 vaccine development protocol: PSV Based Neutralization Assay Abstract The vaccine helps to provoke the immune system and is an efficacious means for disease prevention and treatment. At this particular time of the COVID-19 outbreak, the vaccine for COVID-19 is urgently needed to save tens of thousands of people’s lives. Here we give some basic […]

GeneMedi Efficacy Assay/Evaluation Solutions for COVID-19 Vaccines and Therapeutic antibodies against SARS-CoV2(2019nCoV)

1. GeneMedi information and products collection of SARS-COV-2 (2019nCOV) UK B.1.1.7 lineage and South Africa 501Y.V2 lineage and Brazilian P.1 lineage(B.1.1.28.1) Background Reading:Information and products collection of SARS-COV-2 (2019nCOV) UK B.1.1.7 lineageInformation and products collection of SARS-COV-2 (2019nCOV) South Africa 501Y.V2 lineageinformation and products collection of SARS-COV-2 (2019nCOV) Brazilian P.1 lineage (B.1.1.28.1) GeneMedi pseudotyped virus […]

Challenge of COVID-19 vaccine discovery & development

PSV validated Data Poster Download Protocol Download BACKGROUND Challenge of COVID-19 vaccine discovery & development: to meet accumulated mutating of SARS-CoV-2 and a long-term viral genome transcrption COVID-19 (Coronavirus Disease 2019) is novel viral pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, also called 2019nCoV). The world is in midst of the COVID-19 […]

Comparison among several kinds of novel vaccines

COVID-19 vaccine development protocol: PSV Based Neutralization Assay Comparison among several kinds of novel vaccines Different kinds of vaccines have their specific advantages and disadvantages (Table 13), and people should select the most suitable vaccines according to their demands. Although nucleic acid-based vaccines need short-term and little cost, DNA-based vaccines provoke mild immune responses, and […]

COVID-19 pandemic, Coronavirus (Coronavirus) and genome of SARS-CoV-2 (2019nCoV)

About COVID-19 pandemic, Coronavirus (Coronavirus) and genome of SARS-CoV-2 (2019nCoV) COVID-19 pandemic is caused by 2019nCoV (SARS-CoV-2, a novel coronavirus) infection.The 2019-nCoV genome was annotated to possess 14 ORFs encoding 27 proteins1. Figure. Schematic representative of genome structure and encoded gene of SARS-CoV-2 (2019nCoV)1 Table.Genome Annotation of 2019-nCoV1     Protein length(aa) orf1a 266-13483 4405 […]

SARS-CoV-2 (2019nCoV, novel Coronavirus)Non-structure protein (Nsp1-Nsp16)

About SARS-CoV-2 (2019nCoV, novel Coronavirus)Non-structure protein (Nsp1-Nsp16) 2019nCoV contains 16 Non-structure protein (Nsp1-Nsp16) that may be drugable targets for antiviral compounds discovery against COVID-191. Non-structure protein(NSP)information of SARS-CoV-2 (2019nCoV)1         nsp1 1 180 180 (leader protein) nsp2 181 818 638 nsp3 819 2763 1945 (Papain-Like proteinase, PLpro) nsp4 2764 3263 500 nsp5 […]

SARS-CoV-2 (2019nCoV, novel Coronavirus) Nucleocapsid protein (Coronavirus N protein)

About SARS-CoV-2 (2019nCoV, novel Coronavirus) Nucleocapsid protein (Coronavirus N protein) 1. SARS-CoV-2 (2019nCoV) N protein: Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. N protein packages the positive strand viral genome RNA into a helical […]

SARS-CoV-2 (2019nCoV, novel Coronavirus) membrane protein (Coronavirus M protein)

About SARS-CoV-2 (2019nCoV, novel Coronavirus) membrane protein (Coronavirus M protein) 1. SARS-CoV-2 (2019nCoV) M protein: Coronavirus M protein is believed to define the shape of the viral envelope,which contains three transmembrane domains. It has a small N-terminal glycosylated ectodomain and a much larger C-terminal endodomain that extends 6–8 nm into the viral particle. M protein usualy exists […]